暗盘资金流向曝光！提前捕捉庄家建仓信号>> 脑机接口板块异动走高，创新医疗（002173）涨停，翔宇医疗、海格通信（002465）、佳禾智能 （300793）、三博脑科（301293）、九州通（600998）等跟涨。 ...

5月29日，创新医疗今日收盘10.56元，上涨1.83%，最新市净率2.64，总市值46.60亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.93亿元，同比-3.98%；净利润-13937418.26 元，同比-368.03%，销售毛利率8.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8创新医疗-44.42-49.602.6446.60亿行业平均 39.3945.553.43156.67亿行业中值44.3052.552.7058.27亿1润达医疗-291.91193.172.52106.79亿2何氏眼 科-139.92-121.761.7533.36亿3*ST生物-120.25-116.909.8823.20亿4诚达药业-72.65-124.471.6334.98亿5普 瑞眼科-66.22-59.492.8460.60亿6皓宸医疗-52.07-62.636.1823.60亿7国际医学-45.20-45.453.24115.51亿9金 域医学-35.08-35.921.99136.94亿10百诚医药-33.59-82.011.6943.25亿11迪安诊断-22.59-25.3 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown a recent net value increase of 2.02% and a year-to-date return of 39.18% [1] - The fund's recent performance includes a one-month return of -0.39%, a six-month return of 25.97%, and a year-to-date return ranking of 40 out of 4544 in its category [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has a latest net value of 1.6494 yuan, reflecting a decrease of 2.04% [1] - The fund's performance over the past month shows a return of -0.28%, ranking 3221 out of 3909 in its category; over the past six months, it has achieved a return of 25.90%, ranking 82 out of 3796; and since the beginning of the year, it has returned 39.14%, ranking 35 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on management roles for other funds within the company [2]

Group 1 - The company approved a guarantee for its wholly-owned subsidiary, Zhejiang Hongrun Pharmaceutical Co., Ltd., to secure a loan of up to 8 million yuan from China Merchants Bank [1][2] - The total amount of guarantees provided by the company to its subsidiaries, including this new guarantee, is 54 million yuan, which accounts for 3.04% of the company's most recent audited net assets [2] - There are no overdue guarantees or guarantees involving litigation, and all guarantees are exclusively for subsidiaries [2] Group 2 - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank, which includes various fees and costs related to the guarantee [1][2] - The guarantee period extends for three years beyond the expiration of any specific credit extension [2] - The company has disclosed the relevant announcement in multiple financial publications and on its official information platform [1]

证券代码：002173 证券简称：创新医疗 公告编号：2025-028 创新医疗管理股份有限公司 关于为鸿润医药提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 近日，公司与招商银行诸暨支行签署了《最高额不可撤销担保书》（合同编 号：571XY250512T00000101），具体内容如下： 1、债权人：招商银行股份有限公司绍兴诸暨支行 创新医疗管理股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 的第六届董事会 2025 年第三次临时会议审议通过了《关于为鸿润医药提供担保 的议案》，同意公司为全资控股子公司浙江鸿润医药有限公司（以下简称"鸿润 医药"）在 800 万元授信额度内向招商银行股份有限公司绍兴诸暨支行（以下简 称"招商银行诸暨支行"）申请贷款提供担保。具体内容详见公司于 2025 年 5 月 15 日披露于《证券时报》、《证券日报》、《上海证券报》、《中国证券报》和巨 潮资讯网（www.cninfo.com.cn）的相关公告。 2、保证人：创新医疗管理股份有限公司 二、担保进展情况 3、 ...

Core Viewpoint - The establishment of the Tongchuan Traditional Chinese Medicine (TCM) Medical Group represents a significant step in promoting the innovation and development of TCM in response to national policies [8]. Group Formation - The Tongchuan TCM Medical Group was officially inaugurated at Beijing University of Chinese Medicine, with over 150 attendees from various health and regulatory bodies [1][4]. - Key leaders, including Zhao Xiaolong and Jin Kangpeng, participated in the unveiling ceremony, emphasizing the collaborative effort among 17 member units [4][5]. Objectives and Strategies - The group aims to create a regional medical model that integrates TCM services with Western medicine, focusing on resource sharing and complementary advantages [8]. - The initiative includes implementing "ten integrated" management measures, which encompass aspects like party leadership, medical management, and quality control in TCM practices [8]. - The group plans to establish a new framework for TCM services, including dual-direction patient referrals and remote collaborative interactions, to enhance healthcare delivery in the region [8].

Group 1 - The pilot program aims to promote the full-chain innovation development of medical devices, including R&D design, clinical evaluation, pilot application, iterative upgrades, and radiation promotion [1] - The first batch of innovative medical device integration application pilot list in Sichuan Province includes 40 innovative medical device products, such as cardiac pulse field ablation instruments and SPECT/CT systems [1] - The pilot program will provide support for the construction of provincial medical enterprise joint laboratories and training bases, as well as recommend high-end medical equipment promotion projects [1] Group 2 - The Sichuan Provincial Implementation Plan for Promoting Innovative Medical Device Integration Application specifies that the pilot will be led by one local medical institution and one provincial medical device manufacturer [1] - Chengdu Yongxin Medical Equipment Co., Ltd. has developed a SPECT/CT system that fills a domestic gap and meets international advanced standards, but faces challenges in gaining user trust due to reliance on imported high-end medical equipment [1] - Sichuan Jinjiang Electronic Medical Device Technology Co., Ltd. is leading a pilot for the application of domestic pulse ablation catheters for early atrial fibrillation combined with diastolic heart failure, aiming to establish clinical usage and operational processes [2]

Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of May 23, 2025, the latest net value of the fund is 1.7095 yuan, with a recent decline of 0.86% [1] - The fund's one-month return is 1.79%, ranking 1325 out of 2536 in its category; the six-month return is 31.89%, ranking 26 out of 2456; and the year-to-date return is 42.07%, ranking 14 out of 2485 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed A fund account for a total of 70.44%, with the largest holdings being Kelun-Botai (9.77%), XD Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry before joining Zhongyin Fund Management in 2022 [2]

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has shown a net value of 1.6131 yuan, with a growth of 0.89% [1] - The fund's performance over the past month has yielded a return of 3.96%, ranking 2826 out of 4687 in its category; over the past six months, it has achieved a return of 31.50%, ranking 72 out of 4527; and since the beginning of the year, it has returned 36.08%, ranking 41 out of 4580 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held positions at various financial institutions, including as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on managerial roles for other funds within the company [2]